Physician profile
Walter O Bruning
NPI 1063419901
$21,534.64
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,579 · 2020: $1,801 · 2021: $4,299 · 2022: $5,268 · 2023: $4,033 · 2024: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,587.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,369.02 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,741.63 | 2019-2023 | Otezla, Evenity, Repatha |
| Glaxosmithkline, LLC. | $1,604.53 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $1,448.34 | 2019-2022 | |
| Abbvie INC. | $1,385.69 | 2019-2023 | Vraylar, Ubrelvy, Synthroid |
| Novartis Pharmaceuticals Corporation | $1,335.95 | 2019-2024 | Entresto, Leqvio |
| Novo Nordisk INC | $1,255.35 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,131.80 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $1,021.00 | 2019-2023 | |
| Amarin Pharma, INC. | $664.24 | 2019-2023 | |
| Esperion Therapeutics, INC. | $592.22 | 2021-2023 | Nexletol |
| Lilly USA, LLC | $526.76 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Otsuka America Pharmaceutical, INC. | $496.91 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $380.30 | 2019-2022 | |
| Medtronic, INC. | $335.69 | 2023-2024 | Synchromedii, Minimed 780g |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Bruning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.